1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Indolent Lymphoma Global Clinical Trials Review, H1, 2016

Indolent Lymphoma Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Indolent Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Indolent Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Indolent Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Indolent Lymphoma Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Indolent Lymphoma Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 272
Abbreviations 272
Definitions 272
Research Methodology 273
Secondary Research 273
About GlobalData 274
Contact Us 274
Disclaimer 274
Source 275

List of Tables
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Indolent Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Indolent Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Indolent Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Indolent Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Indolent Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Indolent Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Indolent Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Indolent Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Indolent Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Indolent Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Indolent Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Indolent Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Indolent Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Indolent Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Indolent Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Indolent Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Indolent Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Indolent Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Indolent Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Indolent Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Indolent Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Indolent Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Indolent Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Indolent Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Indolent Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Indolent Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Indolent Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Indolent Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 273

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.